Clinical Trials | A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02

The University of Virginia Comprehensive Cancer Center seeks participants ages 18 and over with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer that have recovered from any previous treatment. The purpose of this study is to learn more about olomorasib, a possible new investigational drug, in combination with standard of care immunotherapy for the treatment of NSCLC. There are 2 parts to the study, Part A and Part B. Your study doctor will determine which part you will benefit most from participating in depending on the stage of disease and prior treatment history. All participants in Part A will receive the standard of care medication, pembrolizumab, along with olomorasib or placebo. All participants in Part B will receive the standard of care medication, durvalumab, along with olomorasib or placebo. Participants will receive combination treatment for up to approximately 1 year, followed by olomorasib or placebo monotherapy to complete up to 3 years of total treatment. The short-term follow-up period of the study begins when you and your study doctor decide that you will no longer receive the study drug, and it lasts for about 30 days. After short-term follow-up period, you will have a long-term follow-up period which lasts until the end of study, withdrawal of consent, or loss to follow-up or death, whichever is earlier. Additional information found here: Study Details | Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer | ClinicalTrials.gov For questions, contact: [email protected]